IRBESARTAN,
Phase 3Small molecule
IRBESARTAN, is one of 47 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
92 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Lithobid
SSolvay Pharmaceuticals
Approved
Calciparine
BBaxter Healthcare Corporation
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Oraverse
LLife Extension Foundation Inc.
Phase 3
Northera
LundbeckPhase 2
Desferal
Jazz PharmaceuticalsPhase 2
Lamisil
NovartisPhase 2
Pitressin
AAultman Health Foundation
Phase 2
Arginine Vasopressin
SStanford University
Phase 3
Jardiance
Boehringer IngelheimPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IRBESARTAN,. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details